Skip to main content

CuraGen Looking at 'Strategic Options' for 454 as Unit's Revenues Soar in Q2

NEW YORK (GenomeWeb News) – CuraGen hired investment bank Goldman Sachs “to examine strategic options" for its investment in 454 Life Sciences, the company said today.
 
It did not provide additional information about this new strategy.
 
CuraGen made the disclosure as it reported that revenue from 454 helped overall receipts more than double.
  
CuraGen's total revenues for the three months ended June 30 surged to $10.7 million from $4.3 million during the same period a year ago. 454 contributed $9.8 million in revenues for the quarter, almost three times more than the same period last year.
454's receipts included $5.4 million from sales of its GS20 DNA sequencer and reagents and $2.3 million in service revenue from its sequencing center.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.